OCULAR THERAPEUTIX, INC Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
OCULAR THERAPEUTIX, INC (OCUL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $38.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2020-03-12
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-09-30 was $3.00M, a 79.57% decline year-over-year.
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-06-30 was $22.70M, a 9.20% decline year-over-year.
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2017-03-31 was $12.50M, a 50.00% decline year-over-year.
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $38.20M, a 52.65% decline from fiscal 2016.
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $80.68M, a 47.16% increase from fiscal 2015.
- OCULAR THERAPEUTIX, INC proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2015 was $54.83M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $3.00M derived: sum of 2 quarters · filed 2020-03-12 | $25.70M derived: sum of 3 quarters · filed 2020-03-12 | $38.20M 10-K · filed 2020-03-12 |
| 2017-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $25.70M derived: sum of 2 quarters · filed 2018-11-07 | $38.20M 10-Q · filed 2018-11-07 | $54.20M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $22.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $35.20M 10-Q · filed 2018-08-07 | $51.20M derived: sum of 3 quarters · filed 2019-03-07 | $65.88M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $12.50M 10-Q · filed 2018-05-08 | $28.50M derived: sum of 2 quarters · filed 2019-03-07 | $43.18M derived: sum of 3 quarters · filed 2019-03-07 | $68.18M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $30.68M derived: sum of 2 quarters · filed 2019-03-07 | $55.68M derived: sum of 3 quarters · filed 2019-03-07 | $80.68M 10-K · filed 2019-03-07 |
| 2016-09-30 | $14.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $39.68M derived: sum of 2 quarters · filed 2017-11-07 | $64.68M 10-Q · filed 2017-11-07 | $79.68M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $50.00M 10-Q · filed 2017-08-08 | $65.00M derived: sum of 3 quarters · filed 2018-03-08 | $95.00M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $25.00M 10-Q · filed 2017-05-05 | $40.00M derived: sum of 2 quarters · filed 2018-03-08 | $70.00M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2015-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $45.00M derived: sum of 2 quarters · filed 2018-03-08 | $54.83M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $30.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $39.83M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $9.83M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |